ArticleAIDS research and therapy2026
HIV viral load suppression and associated factors among PLHIV with non-communicable diseases in Uganda's Teso Region: a cross-sectional retrospective study.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs Uganda scales up integrated chronic care, understanding viral load suppression (VLS) among people living with HIV (PLHIV) with non-communicable diseases (NCDs) is critical for optimizing service delivery. This study thus determined VLS among the PLHIV with NCDs and associated factors.
methodsWe conducted a cross-sectional analysis using routine program data from 10 districts in Eastern Uganda and 18 health facilities-three general hospitals, seven health centre (HC) IVs, seven HC IIIs and one Special HIV Clinic. We included PLHIV aged 20 + who were active in care during the April-June 2025 quarter and screened for NCDs (hypertension, diabetes mellitus, anxiety/depression and alcohol abuse). VLS was defined as < 1000 copies/ml. Robust Poisson regression estimated crude and adjusted prevalence ratios (aPRs) for VLS using 95% confidence interval (CI) and p < 0.05 for statistical significance. A forest plot visualized effect sizes and confidence intervals. STATA Corp version 15 was used for the analysis.
resultsAmong 8,306 PLHIV, 62.4% were female, with a mean (Standard Deviation) age of 46.7 years (13.8). Overall VLS was 94.7% (96.72% for PLHIV with NCDs and 94.53% for those without). NCD comorbidity was 8.45%, predominantly hypertension (7%). Crude analysis showed higher VLS among PLHIV with NCDs (PR = 1.023; p = 0.002), but adjusted estimates attenuated (aPR = 1.015; 95% CI 0.999-1.031; p = 0.065). Older age groups (30-39, 40-49, 50+) had significantly higher VLS than those under 30 ( aPR = 1.063; 95% CI 1.034-1.091; p < 0.001), (aPR = 1.073; 95% CI 1.044-1.102; p < 0.001), (aPR = 1.071; 95% CI 1.043-1.100; p < 0.001) respectively. Males had lower VLS than females (aPR = 0.978, 95% CI [0.968, 0.989] p < 0.001). Clients at Health Centre III had reduced VLS (aPR = 0.979 95%CI [0.961, 0.997]; p = 0.023), while Health Centre IV and hospitals showed no significant difference when compared with those in the special clinic.
conclusionVLS among PLHIV with NCDs was comparable to those without, suggesting integrated care may mitigate disparities. However, age, sex, and facility level remain key determinants. Targeted interventions are needed for younger clients, men, and health centre IIIs to sustain viral suppression in the era of integrated health services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.